9-ING-41
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


9-ING-41
Description:
9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents[1][2][3][4].Product Name Alternative:
ElraglusibUNSPSC:
12352005Hazard Statement:
H301, H311, H331, H341Target:
Apoptosis; Autophagy; GSK-3Type:
Reference compoundRelated Pathways:
Apoptosis; Autophagy; PI3K/Akt/mTOR; Stem Cell/WntApplications:
Cancer-Kinase/proteaseField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/9-ing-41.htmlPurity:
99.13Solubility:
DMSO : 50 mg/mL (ultrasonic)Smiles:
O=C(C(C1=COC2=CC=C(F)C=C12)=C3C4=CN(C)C5=C4C=C6C(OCO6)=C5)NC3=OMolecular Formula:
C22H13FN2O5Molecular Weight:
404.35Precautions:
H301, H311, H331, H341References & Citations:
[1]Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29 (8) :717-724.|[2]Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134 (4) :363-373.|[3]Irina N Gaisina, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl- (indol-3-yl) maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52 (7) :1853-63.|[4]Hiroo Kuroki, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9 (1) :19977.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
Phase 2Isoform:
GSK-3βCAS Number:
[1034895-42-5]
